



DEPARTMENT OF HEALTH & HUMAN SERVICES

MAY 21 2001

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Gary L. Norman, Ph.D.  
Senior Scientist  
INOVA Diagnostics, Inc.  
10180 Scripps Ranch Boulevard  
San Diego, California 92131-1234

Re: K000733  
Trade Name: QUANTA Lite™ ASCA (S. cerevisiae) IgA ELISA  
Regulation Number: 21 CFR § 866.5660  
Regulatory Class: II  
Product Code: NBT  
Dated: March 23, 2001  
Received: April 30, 2001

Dear Dr. Norman:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive style with a large, stylized 'S' and 'G'.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health


Enclosure

510(k) Number (if known): K000733

Device Name: QUANTA Lite™ ASCA (*S. cerevisiae*) IgA ELISA

**Indications For Use:**

The QUANTA Lite™ ASCA (*S. cerevisiae*) IgA kit is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of anti-*Saccharomyces cerevisiae* antibodies (ASCA) of the IgA class in human serum. This test, in conjunction with clinical findings and other laboratory tests, may aid in the diagnosis of patients with Crohn's disease. The QUANTA Lite™ ASCA (*S. cerevisiae*) IgA kit should not be used as a screening test for ASCA since some Crohn's disease patients do not have ASCA IgA antibodies. The Quanta Lite™ ASCA (*S. cerevisiae*) IgA ELISA should be used to complement, but not to replace or substitute for ASCA IgG antibody testing.

  
 \_\_\_\_\_  
 (Division Sign-Off)  
 Division of Clinical Laboratory Devices  
 510(k) Number K000733

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

\_\_\_\_\_  
 \_\_\_\_\_

**Concurrence of CDRH, Office of Device Evaluation (ODE)**

Prescription Use ✓  
 (Per 21 CFR 801.109)

OR

Over-The-Counter Use \_\_\_\_\_

(Optional Format 1-2-96)